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EDITORIAL REVIEW
Endothelium-derived relaxing and contracting factors:
Perspectives in nephrology
The fact that the endothelium can profoundly affect the
function of vascular smooth muscle cells has been recognized
only recently. In 1980, Furchgott and Zawadzki demonstrated
that the relaxation of isolated arteries induced by acetylcholine
requires the presence of endothelial cells (Fig. 1) [1]. Bilayer
experiments in which the relaxation induced by the muscarinic
agonist could be transferred from a vascular segment with
endothelium, to one without, indicated that an endothelium-
derived diffusible substance must be involved [1—3]. This was
confirmed in bioassay experiments demonstrating that arterial
rings without endothelium (bioassay ring) relax in response to
acetylcholine or bradykinin only if they were superfused with
physiological salt solution passing through either a column with
cultured endothelial cells or an arterial segment with endothe-
hum [4—7]. The unknown substance was named endothehium-
derived relaxing factor (EDRF) [1—81 (Fig. 2). More recently it
has been recognized that the endothelium can also produce
constrictor substances [2, 31. This article updates previous
reviews on endothelium-derived relaxing and contracting fac-
tors [9—111 and focuses on their potential importance in nephrol-
ogy.
Nature and action of endothelium-derived relaxing factor
Since endothelial cells are a major source of prostacyclin, the
prostanoid at first appeared to be the most likely mediator of
endothelium-dependent relaxations [1, 2, 121. The inability of
cyclooxygenase inhibitors to prevent endothelium-dependent
relaxations and the fact that the response also occurred in blood
vessels which do not relax to the prostanoid (that is, rabbit and
rat aorta) [1, 13], however, excluded prostacyclin as the medi-
ator.
Bioassay experiments in which the transit time between the
donor and recipient blood vessel could be altered revealed a
biological half-life of EDRF in the range of a few seconds,
indicating that a very labile substance was involved [4—7, 14].
The fact that superoxide anions destroyed EDRF, while the free
radical scavenger superoxide dismutase prolonged its half-life
suggested that the mediator is inactivated by the radicals
[14—16].
Early on, it was noted that the relaxations induced by
acetylcholine are associated with an increase in cyclic guano-
sine 3',5'-monophosphate (cGMP) levels in vascular smooth
muscle cells [17]. Since nitrovasodilators also increase cGMP
[18, 19], this indicated that EDRF might represent an endoge-
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nous nitrate. Furchgott [20] and Ignarro [21] independently
proposed that nitric oxide might account for the biological
activity of EDRF. Indeed, nitric oxide can evoke relaxation and
increases in intracellular cGMP levels of vascular smooth
muscle cells 122]; similarly, the free radical is the active
component of nitrovasodilators [23]. Palmer, Ferrige and Mon-
cada demonstrated that bradykinin releases nitric oxide from
cultured endothelial cells; in addition, the biological half-life
and the vascular activity of exogenously added nitric oxide
were indistinguishable from those of EDRF released by the
cells (Fig. 2) [24]. Thus, nitric oxide represents the endogenous
nitrovasodilator in the circulation [22]. As activated macro-
phages [25], endothelial cells cleave nitric oxide from L-argi-
nine by specific cytosolic enzyme [26—28]. Although the chem-
ical nature of this reaction is not fully understood yet, the
available evidence suggests that hydroxylation of L-arginine is
the first step in the reaction leading to NGhydroxyLarginine
[28]. Further, a conversion of this intermediate to NGoxoL
arginine and finally to N = 0, N02, N03 and L-citrulline has
been proposed [28]. The oxidation of arginine to citrulline is
supported by NADPH, but not NADH or ascorbic acid [29] and
can be inhibited by the methylated analogue of the precursor
aminoacid LNGmonomethyl arginine [25, 27, 28]. Debate
continues on whether the endogenous nitrate is released as
nitric oxide or whether a carrier molecule (for instance L-cys-
teine) [30] secures the transit of the labile mediator to the
effector cell. The formation of nitric oxide from L-arginine is
not specific for endothelial cells, but has also been demon-
strated in neuronal cells [31], neutrophils [32] and macrophages
[25].
In isolated blood vessels [1, 8, 33] and in the human forearm
in vivo [34], endothelium-derived relaxing factor is a very
potent vasodilator comparable to sodium nitroprusside. In
addition to its vasodilator effect, nitric oxide is a potent
inhibitor of platelet adhesion and aggregation, indicating that it
importantly contributes to the thromboresistant properties of
the endothelium [35, 36]. Nitric oxide and prostacyclin interact
with each other even at subthreshold concentrations, and
potentiate their antiaggregatory [35] and vascular action (at
least in the porcine coronary artery) [37].
Furthermore, EDRF can interfere with hormonal systems of
cardiovascular regulation. EDRF released from isolated canine
blood vessels during stimulation with acetylcholine [38] and
from porcine endothelial cells in culture with bradykinin [39]
reduces the release of renin by canine kidney slices. In atria of
the rat, removal of the endothelium and the endocardium or
certain inhibitors of EDRF (such as hemoglobin, methylene
blue and hydroquinone) augment the basal release of atrial
natriuretic peptide [40], indicating that EDRF released from the
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Fig. 1. Endothelium-dependent relaxations to
acetyicholine and thrombin in a human renal
artery. NE = Norepinephrine. (Original
recording, modified from ref. 123 with
permission).
Fig. 2. Vasoactive substances released from
the vascular endothelium. Abbreviations are:
AA, arachidonic acid; ACE, angiotensin
converting enzyme; Ach, acetyicholine; ADP,
adenosine diphosphate; AT I/Il, angiotensin
I/LI; cAMP, cyclic adenosine monophosphate;
ATG, angiotensinogen; cGMP, cyclic
guanosine monophosphate; EDCF(s),
endothelium-derived constrictor factor(s);
EDRF(s), endothelium-derived relaxing
factor(s); 5-HT, 5-hydroxytryptamine
(serotonin); PGI2, prostacyclin. Receptors are
represented by an open circle: A =
angiotensinergic; H1/H2 histaminergic
receptor; M = muscarinic receptor; P1 =
purinergic receptor; S1 = serotonergic
receptor; T = thrombin receptor; V =
vasopressinergic receptor. (modified from ref.
10, by permission).
endocardium or the endothelium of the coronary vasculature
inhibits the release of atrial natriuretic peptide.
Are there other endorhelium-derived relaxing factors?
Although prostacyclin has been excluded as the mediator of
endothelium-dependent relaxations induced by acetylcholine
[1], the prostanoid may act as an endothelium-derived relaxing
factor, if released in sufficient quantities abluminally and if the
underlying vascular smooth muscle is sensitive to it (Fig. 2)
[121. In the strict sense, however, the prostanoid is not an
endothelium-derived relaxing factor as it is also produced in
significant amounts by vascular smooth muscle F 121. In contrast
to nitric oxide which stimulates the production of cGMP,
prostacyclin increases intracellular cAMP levels of vascular
smooth muscle cells and platelets [12, 411. A variety of stimuli
which activate the release of EDRF, such as shear stress (flow),
increase in intracellular calcium levels and activation of recep-
tor-operated mechanisms by acetylcholine, bradykinin, throm-
bin, angiotensin II and histamine also evoke the release of
prostacyclin [2]. In most preparations—except the renal and
mesenteric artery of the dog [42, 431—, however, prostacyclin
contributes very little or not at all to endothelium-dependent
relaxations [1, 2, 33]. Indeed, in isolated human arteries and the
human forearm circulation studied in vivo, inhibitors of cyclo-
oxygenase do not reduce endothelium-dependent relaxation to
acetylcholine [33, 34]. Possibly, larger amounts of the pros-
Liischer et al: Endothelium derived factors 577
tanoid are released towards the lumen of blood vessels (to
interact with circulating platelets) than towards vascular
smooth muscle [44]. Since EDRF and prostacyclin act syner-
gistically to inhibit platelets [35], even small amounts of the
prostanoid (released abluminally) may importantly contribute
to the thromboresistant properties of the endothelium.
In addition, the endothelium must release an endothelium-
derived hyperpolarizing factor (EDHF) (Fig. 2) [45]. The evi-
dence for such a factor is based on pharmacological and
electrophysiological data. In canine arteries, relaxations in-
duced by acetylcholine and arachidonic acid are reduced by the
Na, K-ATPase inhibitor ouabain [46, 47]. Acetylcholine
causes an endothelium-dependent increase in membrane poten-
tial of vascular smooth muscle cells and this effect can be
transferred from a vascular segment with endothetium to one
without endothelium, indicating that a diffusible mediator is
involved [48]. Since, at least in canine smooth muscle, the
hyperpolarization can be prevented with ouabain [48], the
response appears to depend on the activity of the electrogenic
Na, K-pump. Nitric oxide, however, does not affect the
membrane potential under these conditions [49, 50]. Thus, the
endothelium of certain arteries must release a relaxing factor
distinct from nitric oxide. The most likely candidate is an
endothelium-derived hyperpolarizing factor (EDHF) activating
either the Nat, K-pump [45, 48, 51] or ATP-sensitive potas-
sium channels [52]. EDHF may contribute to the sustained
phase of vascular relaxation and/or render the smooth muscle
cells less responsive to vasoconstrictor stimuli, particularly
those agonists which decrease membrane potential. Although
endothelial cells can produce adenosine and ammonia, their
putative role as endothelium-derived relaxing factors remains
undefined [2]. They both do not affect membrane potential [2;
Komori K, Vanhoutte, personal communication].
Endothelial cells in culture contain large amounts of platelet
activating factor (PAF) [53, 54]. Its release from the cells can be
stimulated by the calcium ionophore A23 187, adenosine
triphosphate (ATP), bradykinin and angiotensin II [2, 53, 54]. It
is unknown whether PAF is released in sufficient amounts to
evoke biological effects in vascular smooth muscle or endothe-
hal cells. If it is, PAF may act as an EDHF as it hyperpolarizes
endothelial cells [55], although such an effect may be offset by
its direct contractile effects at least in certain vascular beds.
Tissue plasminogen activator (TPA) is a product of endothe-
hal cells [56, 57]. The substance is released in response to
thrombin, arginine vasopressin, bradykinin and fluid flow. It is
a potent fibrinolytic agent which now is widely used in myocar-
dial infarction [58]. Thus, TPA—together with EDRF and
prostacyclin—may be part of a protective system in the circu-
lation which prevents thrombus formation, vasospasm and
vascular occlusion.
Endothelium-derived contracting factors
Endothelial cells can also mediate vasoconstriction (Fig. 2)
12, 3]. The nature of most endothelium-derived contracting
factors (EDCF) such as angiotensin II, endothelin and those
derived from the cyclooxygenase pathway (that is, thrombox-
ane A2 and prostaglandin H2) is known, while that of the
endothehium-derived contracting factor (EDCF1) released dur-
ing hypoxia remains to be elucidated.
The vascular wall renin-angiotensin system has been well
characterized biochemically [59, 60]. Cultured endothelial cells
contain renin-like activities [61]. Immunoreactive angiotensin-
ogen as well as angiotensin I, II and III can be detected in these
cells [62]. Endothelial cells are also important in the conversion
of circulating angiotensin I into the biologically active angioten-
sin II [63]. Besides its role in the conversion of the peptide, it
remains uncertain, however, whether components of the endo-
thelial renin-angiotensin system importantly contribute to vas-
cular regulation.
Bovine and porcine endothelial cells in culture and of the
intact porcine aorta release a potent 21-residue vasoconstrictor
peptide, endothelin [64—68]. Endothehin is generated from pre-
cursor molecules (that is, preproendothelin, proendothelin).
Expression of preproendothelin mRNA can be stimulated by
thrombin, transforming growth factor /3, adrenalin, angiotensin
II, interleukin 1, arginine vasopressin, phorbol ester and cal-
cium ionophore A23 187 [69]. In the intact porcine aorta, endo-
thelin is released under basal conditions and after stimulation
by thrombin and the calcium ionophore A23 187 [68]. Significant
amounts of the peptide can be detected four hours after
stimulation; the production is fully endothehium-dependent and
requires de novo protein synthesis as cycloheximide (an inhib-
itor of protein synthesis) prevents the release of the peptide
[68]. Thus, endothelin does not appear to be stored in intracel-
lular granules. In intact arteries, the thrombin-stimulated re-
lease of endothelin is inhibited by endothelium-derived nitric
oxide which is formed concomitantly during stimulation with
the enzyme via a cyclic GMP-dependent mechanism [681. It is
noteworthy that, although coagulation products stimulate the
release of endothelin, the peptide—in contrast to EDRF and
prostacyclin—does not affect platelet function.
The peptide causes contraction of isolated arteries and veins
also in those obtained from humans [66, 69—731 and induces
sustained blood pressure elevations when infused into intact
animals [66, 74-76]. Of the three forms of the peptide endothe-
lin-2 is the most potent vasoconstrictor, followed by endothe-
lin- 1 (formerly human or porcine) and endothehin-3 (formerly
rat) [69, 77]. Endothelial cells can only release endothehin-1.
The expression of endothehin-2 has not been demonstrated in
any tissue yet, while endothehin-3-like immunoreactive material
has been found in porcine brain homogenate [69]. Thus, endo-
thelin-3 may represent a neural form of the peptide.
On vascular smooth muscle membranes, the peptide binds to
specific membrane receptors [78] where it activates phospholi-
pase C and in turn the phosphoinositol metabolism, and induces
increases in intracellular calcium [79—81]. Direct activation of
dihydropyridine-sensitive calcium channels does not occur,
since the binding of iodinated Ca2-antagonists is unaffected by
endothelin [78]. In certain preparations such as the porcine
coronary artery, endothelin receptors are linked to voltage-
operated calcium channels via a G1-protein [82]. This may
explain why calcium channel antagonists such as nifedipine,
nicardipine, and diltiazem do not prevent the contractions
induced by the peptide in most preparations, particularly in
large conduit arteries [72, 73; Yang Z, Lüscher TT; personal
communication]. However, in isolated resistance arteries of the
rat [83] as well as in the rat renal vasculature [84] and in the
human forearm circulation studied in vivo [Linder L, Kiowski
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W, Buhler FR, LUscher TF, unpublished observation] the drugs
are effective. In addition to its direct contractile effects, thresh-
old concentrations of endothelin can augment the action of
other vasoconstrictor hormones such as norepinephrine and
serotonin [85—871. This indirect contractile effects of endothelin
do involve activation of voltage-operated calcium channels as
darodipine prevents the potentiation of the response to norepi-
nephrine induced by endothelin [85].
In vivo, and in perfused vascular beds, the peptide can cause
a transient vasodilatation lasting for seconds [66, 88—91]. This
depressor response is more pronounced with endothelin-3 than
with endothelin-l, suggesting that different receptor subtypes
are involved [69]. Most likely, the vasodilator properties of the
peptides are related to stimulation of the release of EDRF,
prostacyclin and/or atrial natriuretic peptide [69, 89—92]. In
perfused mesenteric resistance arteries and in the perfused
mesenteric bed, this vasodilatation occurs only with intralumi-
nal administration of low concentrations of endothelin, while
higher concentrations evoke contractions [911. Since the relax-
ation is endothelium-dependent and prevented by indometh-
acm endothelium-derived prostacyclin is the most likely medi-
ator [91]. In contrast, the response to intravenous endothelin is
always preceded by a vasodilatation [66, 69]; most likely, atrial
natriuretic peptide is the more important mediator of this
response in vivo [92].
The cyclooxygenase pathway of endothelial cells is a source
of contracting material such as thromboxane A2, prostaglandin
H2 and superoxide anions (Fig. 2) [2]. In the rat renal artery and
aorta as well as in the basilar artery of the dog, acetyicholine
and mechanical stretch cause endothelium-deperident contrac-
tions [13, 93—96] which are blocked by inhibitors of the cyclo-
oxygenase pathway [13, 93—95]. In canine veins, exogenous
arachidonic acid induces endothelium-dependent contractions
which are blocked by inhibitors of cyclooxygenase, but not
those of prostacyclin or thromboxane synthetase [97]. Thus,
the endotheliurn must release a contracting substance(s)
[EDCF(s)2] distinct from thromboxane A2 after activation of the
cyclooxygenase pathway (Fig. 2) [2]. Prostaglandin H2 and
superoxide anions (which are formed during activation of the
cascade) are mediators of endothelium-dependent contractions
in the rat aorta (after stimulation with acetylcholine) [98] and
the canine basilar artery (after stimulation with the calcium
ionophore A23 187) [99], respectively.
In canine coronary arteries severe hypoxia elicits endotheli-
urn-dependent contractions [3, 100, 101]. In layered prepara-
tions, the contractions can be transferred from a donor segment
with endothelium to a coronary artery strip without endothe-
hum, demonstrating the release of a diffusible contracting factor
[3]. These endothelium-dependent contractions are unaffected
by trypsin (excluding a peptide such as endothelin) or inhibitors
of the metabolism of arachidonic acid [excluding a cyclooxyge-
nase-dependent contracting factor (EDCF2) as the mediator [3,
102]. Similarly, hypoxia or anoxia augment contractile re-
sponses in canine femoral and cerebral arteries [100, 101]. This
augmentation is reduced by endothelial removal, but unaffected
by indomethacin. It is unlikely that the endothelium-derived
contracting factor released under hypoxic conditions is endo-
thelin, since the response is rapid, unaffected by trypsin and can
be prevented by calcium antagonists [102].
Physiologic role of endothelium-derived relaxing and
contracting factors
Endothelium-derived vasoactive substances are released un-
der basal conditions and after stimulation with physical stimuli
(such as shear stress, pressure, hypoxia) or autacoids and
hormones [2]. A considerable heterogeneity of these responses
exists, however, ithin blood vessels of different anatomical
origin and from different species [2].
The basal formation of nitric oxide can modulate vascular
reactivity. Indeed, the presence of the endothehium inhibits
contractions induced by norepinephrine, serotonin and endo-
theliii,,and this inhibition is in large parts prevented by
L-NMMA [2, 103, 104]. Similarly, infusion of L-NMMA mark-
edly increases peripheral vascular resistance [105] and blood
pressure [106], indicating that EDRF takes part in blood pres-
sure regulation.
Endothelin also is released under basal conditions [69, 107].
As even threshold and low concentrations of the peptide
augment the sensitivity of rat and human arteries [85—87] to
norepinephrine and serotonin, the peptide may importantly
regulate vascular reactivity. Whether the basal formation of
endothelin-1 in intact blood vessels is sufficient to exert such
effects, however, is still uncertain.
Shear stress-induced EDRF release accounts for flow-in-
duced vasodilatation in large arteries, for instance during exer-
cise [108, 109]. Whether stretch-induced endothelium-depen-
dent contractions contribute to the autoregulatory response has
to be further substantiated [95, 96]. If the response were to
occur in the microcirculation in vivo, it might play a role in the
autoregulation of blood flow. Stretch-activated ion channels
have been described in vascular endothelial cells [110]. The
channels are permeable to calcium and their opening frequency
responds to stretch. The channels may explain how the endo-
thelium senses and responds to mechanical forces such as flow
and shear stress. Indeed, in the rat aorta, endothelium-depen-
dent contractions to stretch are dependent on extracellular
calcium [96]. Hypoxia-induced endothelium-dependent con-
tractions [3, 111] may be particularly important in the pulmo-
nary circulation in the regulation of ventilation-perfusion cou-
pling.
In some arteries, norepinephrine activates endothelial alpha2-
receptors linked to the release of nitric oxide [112, 113]. In the
canine basilar artery vasopressin induces endothelium-depen-
dent relaxations mediated by V1-vasopressinergic receptors,
while in the renal circulation it evokes contraction [114]. In
large canine renal arteries, angiotensin II causes endothelium-
dependent relaxations via the release of prostacyclin [43]. Thus,
the vascular effects of circulating hormones are profoundly
modulated by basal and stimulated release of EDRF; the
stimulated release differs considerably, however, among dif-
ferent vascular beds depending on the expression of endothelial
receptors.
The physiological role of acetylcholine as a stimulus for the
release of EDRF (Figs. 1 and 3) is not clear, as it is not a
circulating hormone [2]. In isolated resistance arteries acetyl-
choline added extraluminahly can penetrate the vascular wall
and evoke the release of EDRF [115, 116]. Thus, in chohinergi-
cally innervated parts of the microcirculation (such as the
gastric mucosa), EDRF may contribute to the vasodilator
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Fig. 3. Endothelium-dependent relaxations to
acetylcholine in isolated mesenleric resistance
arteries of the rat. Abbreviations are: Hb,
hemoglobin; NE, norepinephrine; SNP,
sodium nitroprusside (from ref. 126, by
permission).
action of the muscarinic agonist [117]. Endothelial cells of small
cerebral arteries contain the enzyme cholinesterase and are
thus capable of producing acetyicholine from its precursor and
may release EDRF by an autocrine mechanism [1181. If acti-
vated in vivo, the muscarinic release of EDRF evokes a very
potent vasodilatation also in humans [34].
Aggregating platelets are a rich source of endothelium-depen-
dent agonists such as adenine nucleotides, serotonin, vasopres-
sin, histamine (at least in certain species) and TGF/3 [2].
Platelet-derived serotonin and adenosine diphosphate (ADP)
induce endothelium-dependent relaxations to aggregating plate-
lets in the porcine, canine and human coronary circulation,
respectively [119—122]. ADP and thrombin—which is formed
after activation of the coagulation cascade—also release EDRF
in human renal arteries (Fig. 1) [2, 123]. Release of EDRF and
prostacyclin, both potent vasodilators and inhibitors of platelet
function, in response to platelet-derived products may be an
important protective mechanism preventing platelet adhesion
and aggregation and in turn vasospasm, thrombus formation
and eventually vascular occlusion (Fig. 4) [2].
Endothelial control of blood pressure
Regulation of peripheral vascular resistance
Several lines of evidence underscore the potential importance
of EDRF in the maintenance of systemic vascular tone. Endo-
thelium-dependent relaxations occur in resistance arteries
where peripheral vascular resistance is regulated (Fig. 3) [2, 91,
115, 116, 124—1261. Infusion of the EDRF inhibitor, hemoglo-
bin, increases blood pressure in normal subjects [127]. In the
intact rabbit and the human forearm circulation, infusion of an
inactive analogue of L-arginine, LNGmonomethyl arginine,
induces a long lasting, dose dependent increase in mean arterial
pressure and peripheral vascular resistance, respectively [105,
1061. In addition, the drug inhibits the vasodilatory response to
subsequent acetylcholine infusion (Fig. 5) [34, 105]. Both ef-
fects can be reversed by reinstitution of L-arginine [105, 106].
This demonstrates that endothelium-derived nitric oxide pro-
foundly affects tone of resistance arteries and in turn blood
pressure both under basal conditions and after receptor-oper-
ated stimulation of its release.
Although exogenous endothelin profoundly affects blood
pressure [66, 69], the circulating levels of endothelin are very
low, but they increase with age [107, 128]. Thus, it is unlikely to
evoke a direct vascular effect as a circulating hormone. How-
ever, it remains possible that endothelin is released in larger
amounts towards vascular smooth muscle cells rather than
towards the vessel lumen. The fact that even threshold levels of
the peptide can upregulate vascular reactivity (see above)
[85—87] suggests that locally produced endothelin may contrib-
ute to the regulation of blood pressure. The exact role of the
peptide in blood pressure regulation awaits experiments with
specific antagonists.
Hypertension
High blood pressure is associated with various functional
changes of the endothelium, including a decreased formation of
relaxing factors, an increased release of contracting factors and
an altered responsiveness of the vascular smooth muscle cells
to the factors [2]. This dysfunction of the hypertensive endo-
thelial organ may contribute to the elevation of peripheral
vascular resistance and/or to the development of the complica-
tions of the disease process in the cerebral, coronary or renal
circulation [2].
Endothelium-dependent relaxations to acetylcholine and
other agonists of EDRF are reduced in most blood vessels
including resistance arteries obtained from rats with chronic
hypertension (Fig. 6) [2, 13, 91, 94, 98, 115, 116, 124—126,
129—133]. Similarly, in the human forearm circulation, the
vasodilator response to acetyicholine is attenuated [34, 134]. In
hypertensive Dahl rats, the reduction of the response to acetyl-
choline correlates with the height of systolic blood pressure [2,
133]; antihypertensive therapy, on the other hand, normalizes
both blood pressure and endothelium-dependent relaxations
[135]. In secondary hypertension, the reduced endothelium-
dependent relaxations most likely are a consequence rather
than a cause of high blood pressure.
A With endothelium B Without endothelium
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Hb iO- M
250 rng
NE3 x 10-6M
Acetylcholine (—log M)
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Different mechanisms contribute to the impaired endotheli-
urn-dependent relaxations in different forms of hypertension. In
the aorta of the spontaneously hypertensive rat, acetyicholine
evokes endothelium-dependent contractions [13]. Similar re-
sponses can be obtained in the aging, but not in the young
Wistar-Kyoto rat suggesting that high blood pressure and aging
promote endothelium-dependent contractions [1361. The re-
sponse is mediated by a cyclooxygenase product other than
prostacyclin or thromboxane A2, most likely prostaglandin H2
(EDCF2) (Fig. 2) [98]. Similarly, in mesenteric resistance arter-
ies of spontaneously hypertensive rats, inhibition of cyclooxy-
genase normalizes endothelium-dependent relaxations to
acetylcholine [125, 126, 137]. Furthermore, in the aorta of
DOCA-hypertensive rats, the endothelium-dependent contrac-
tions to stretch are augmented [96]. Thus, at least in spontane-
ous and DOCA-salt hypertension of the rat, the release of
EDCF2 is augmented and accounts for the altered endothelium-
dependent relaxations. Indeed, bioassay experiments suggest
that, in spontaneous hypertension of the rat, the luminal release
of EDRF and that of prostacyclin is unaltered [2, 131, 138].
The situation differs in salt-induced hypertension of the rat
and possibly in the human forearm circulation [34, 1331, where
the release of EDRF appears to be blunted. Particularly in the
former, a decreased vascular responsiveness to EDRF also
contributes to the reduced endothelium-dependent relaxations.
In contrast, the responsiveness of mesenteric resistance arter-
ies of hypertensive rats to exogenous nitric oxide and sodium
nitroprusside is not reduced [115, 116, 126]. Thus, structural
changes of the media can contribute to the reduced endotheli-
urn-dependent responses particularly in large hypertensive
blood vessels, but the response to acetylcholine is altered even
in the absence of these changes. To judge from the rabbit
carotid artery where extensive subintimal thickening does not
Fig. 4. The endothelium and platelet-vessel
wall interaction. Activated platelets release
several mediators which can interfere with the
endothelium to release endothelium-denved
relaxing factor (EDRF) and in most instances
also prostacyclin (not shown). In human
arteries thrombin (Thr) and adenosine di- and
triphosphate (ADP, ATP) are most important.
Platelets also release transforming growth
factor beta (TGF/3) which—as
thrombin—activates the production of
endothelin. EDRF plays a protective role by
inhibiting platelet function (—), causing
relaxation and also by inhibiting the thrombin-
induced endothelin production (not shown).
Thromboxane A2 (TXA2) and serotonin (5-
HT2) cause contractions in most blood
vessels, but their effects are attenuated by the
endothelium. Open circles represent specific
receptors. All angiotensin 11; Bk bradykinin;
SP substance P; Hst histamine (modified from
refs. 10, by permission).
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Fig. 5. Effect on LNGmonomethyl arginine (L-NMMA; 100 mg/kg
intravenously) on blood pressure (BP) and heart rate (HR) in the
anesthetized rabbit. L-NMMA evokes a marked and sustained rise in
blood pressure and a slight decrease in heart rate (A). Infusion of
L-arginine reverses the effects of L-NMMA (B). (from ref. 106, by
permission).
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reduce endothelium-dependent relaxations [139], structural
changes of the subintima (as they can occur in hypertensive
blood vessels) do not act as a diffusion barrier for EDRF [2].
The circulating levels of endothelin in hypertensive patients
have been found to be normal by two groups [128, 1401, while
one report found elevated levels [1411. It is conceivable that
only a subgroup of patients—possibly a form of hypertension
dependent on the peptide or patients with hypertension-induced
vascular disease—exhibit an increased endothelin production.
Alternatively, the circulating levels may not reflect the local
concentrations of the peptide at the level of vascular smooth
muscle, particularly, if it were preferentially released towards
the abluminal side of the blood vessel wall. Early reports on the
sensitivity of hypertensive arteries to endothelin-1 have yielded
conflicting results [2]. While some found augmented contrac-
tions in the renal artery of the spontaneously hypertensive rat
[142], others observed normal or even reduced responses in
hypertensive blood vessels [91, 142, 143]. The ability of EDRF
(released by acetylcholine) to reverse the contractions induced
by the peptide, however, is impaired in mesenteric resistance
arteries of spontaneously hypertensive rats indicating an imbal-
ance between endothelium-derived relaxing and contracting
factors in hypertension [91, 1431.
With respect to the complications of hypertension, platelet-
endothelial interactions are of great interest as in ischemic
stroke and myocardial infarction, thrombus formation and
vascular occlusion are the major events [2]. In the aorta and
carotid artery of the spontaneously hypertensive rat, endothe-
hum-dependent responses to platelets and platelet-derived
products (that is, ADP, serotonin) and thrombin are altered [2,
94, 135, 144—146]. In the perfused cerebral and coronary circu-
lation of the spontaneously hypertensive rat, the vasodilator
responses of ADP and/or serotonin are lost [2, 147, 148]. The
paradoxical vasoconstriction induced by serotonin in hyperten-
sive rats is prevented by indomethacin, suggesting that it is
mediated by an endothelium-derived (cyclooxygenase-depen-
dent) contracting factor (EDCF2) (Fig. 2) [147, 1481.
In the hypertensive Dahi rat and in man, high dietary potas-
sium supplementation reduces the incidence of strokes indepen-
dent of its effects on blood pressure, suggesting a direct
protective effect of the diet [149, 150]. High dietary potassium
enhances endothelium-dependent relaxations to acetylcholine
(even in the absence of changes in blood pressure) in the aorta
of hypertensive Dahl rats [151]. Antihypertensive therapy nor-
malizes the blunted endothelium-dependent relaxations to ace-
tylcholine, ADP and thrombin in the aorta of hypertensive DahI
rats [135]. This may importantly contribute to the reduced
incidence of cardiovascular events during high potassium diet
and antihypertensive therapy.
Atherosclerosis and diabetes
Atherosclerosis is associated with marked reductions of
endothehium-dependent relaxations to acetylchohine and aden-
osine diphosphate or thrombin in experimental animals and
patients with coronary disease [152—1571. In the rabbit, the
reduction of endothelium-dependent relaxations is directly Fe-
hated to the amount of cholesterol in the diet, the duration of the
diet and the degree of fatty streak formation [1521. In rabbits
with hereditary atherosclerosis (Watanabe rabbits), endothehi-
um-dependent relaxations to acetylchohine are reduced in the
8WKY
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common carotid and renal artery [156]. In patients with coro-
nary artery disease, intracoronary infusion of acetylcholine
causes paradoxical contractions of epicardial coronary artery
segments (while in normal subjects the muscarinic agonist
causes vasodilatation), suggesting that the altered endothelial
function of atherosclerotic arteries can also be demonstrated in
vivo [155]. The main disorder in atherosclerotic arteries is a
decreased release of EDRF [157]. In addition, at least in the
porcine coronary artery, atherosclerosis favors the release of a
cyclooxygenase-dependent contracting factor (EDCF2) [157].
An impaired responsiveness of atherosclerotic arteries to nitro-
vasodilators occurs only at a very late stage of the disease
process [152, 153]. The impaired release of the vasodilator and
inhibitor of platelet function EDRF may explain the reduced
antithrombotic properties and the augmented contractile re-
sponse characteristic of atherosclerotic arteries. Similar
changes as those occurring in atherosclerosis can be induced by
oxidized low-density lipoproteins which are the major compo-
nent of the atherosclerotic plaque [158; Tanner F, Boulanger C,
Lüscher TF, unpublished observations].
In human arteries insulin causes endothelium-dependent Fe-
laxations [159] and infusions of the peptide into the human
forearm circulation evoke vasodilatation [1601. Furthermore,
the hormone reduces endothelin production of human mesan-
gial cells [161]. Diabetes is associated with impaired endothehi-
um-dependent relaxations to acetyicholine [2]. In the corpora
cavernosa circulation of diabetic patients with impotence, this
must be related to an endothelial dysfunction (most likely a
decreased release of EDRF) as the capacity of vascular smooth
muscle to relax to sodium nitroprusside is well maintained
[162]. In the aorta of diabetic rabbits, endothelium-derived
thromboxane A2 is concomitantly released with EDRF leading
the reduced relaxations [163].
Thus, hyperlipidemia, diabetes and atherosclerosis are asso-
ciated with a decreased release of EDRF and, at least under
certain conditions, an increased release of endothehium-derived
Acetyicholine, -log M
SHR
8
Ii
2 mm
5
Norepinephrmne, 1O M
Fig. 6. Endothelium-dependent relaxation to acety/choline in the aorta
of a normotensive Wisiar-Kyoto rat (WKY; top) and in that of a
spontaneously hypertensive rat (SHR; bottom).
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Table 1. Renal effects of endothelium-derived relaxing factor (EDRF)
and endothelin
RBF GFR Ra Re Kf
EDRF (Nitric I a ?b
oxide)
Endothelin I I
Abbreviations are: RBF, renal blood flow; GFR, glomerular filtration
rate; Ra, afferent resistance; Re, efferent resistance; Kf, ultrafiltration
coefficient.
a Most likely the effects of endothelium-dependent vasodilators on
Ra do not involve nitric oxide, but rather another EDRF.
' To judge from the effects of EDRF and nitric oxide in mesangial
cells, K is likely to increase.
contracting factor(s). The reduced thromboresistant properties
of the endothelium (Fig. 4), would increase platelet-vessel wall
interaction and facilitate vasospasm and thrombus formation
and may importantly contribute to cardiovascular morbidity
and mortality in these patients.
Endothelial control of renal function
In the kidney, endothelium-derived substances interact with
vascular smooth muscle, mesangial, juxtaglomerular and pos-
sibly also tubular cells and hence profoundly affect renal
hemodynamics and function.
In isolated human renal arteries, acetyicholine, ADP, throm-
bin and histamine (mediated via endothelial 1-histaminergic
receptors) induce endothelium.dependent relaxations (Fig. 1)
[123]. Acetylcholine and bradykinin have long been known to
increase renal blood flow both in vivo and in isolated perfused
kidneys [164-166]. In interlobular arteries and afferent and
efferent arterioles isolated from the rabbit kidney, acetylcholine
causes concentration-dependent relaxations [1661 and increase
cGMP in canine renal medullary slices [1671. As hemoglobin
inhibits the vasodilatation evoked by acetylcholine only in the
efferent, but not in the afferent arteriole, the muscarinic agonist
appears to release EDRF in the former but another relaxing
factor (see above) in the latter [167, 168] (Table 1). Bradykinin
relaxes efferent arterioles, but exerts no effect in preglomerular
microvessels [1661. In the rat, intravenous infusion of acetyl-
choline causes hypotension, renal vasodilatation and increase
in urinary cGMP excretion, while glomerular filtration rate is
maintained [169]. On the other hand, L-NMMA increases renal
vascular resistance, reduces urinary cGMP excretion and de-
creases renal blood flow, while glomerular filtration rate re-
mains constant [169, 170]. The inhibitor of nitric oxide formation
also prevents the renal hemodynamic effects of acetyicholine.
Interestingly, L-NMMA also attenuates the vasodilator response
to amino acid infusions [170].
Mesangial cells in culture respond with an increase in intra-
cellular cGMP levels after addition of exogenous nitric oxide or
EDRF released from cultured endothelial cells [1711. In addi-
tion, nitric oxide inhibits the angiotensin Il-induced contraction
of mesangial cells [1711.
Endothelin infused into intact dogs or rats, markedly reduces
renal blood flow, glomerular filtration rate and sodium excretion
[75, 172—1751 (Table 1). Interestingly, the renal vasculature
appears to be more sensitive to intravenously applied endothe-
lin than, for instance, the coronary vascular bed [172]. Dc-
creases in renal blood flow occur before changes in arterial
blood pressure are noted [175]. In isolated perfused kidneys of
the rat, the peptide causes profound and long-lasting renal
vasoconstriction and severe decrease in glomerular filtration
rate in a concentration range several times lower than angio-
tensin II [1761. The vasoconstrictor effects of the peptide in the
kidney are limited by the formation of prostaglandin E2 and
prostacyclin [177, 178]. As judged from experiments in the dog,
endothelin-induced contractions are much more resistant to
nitroglycerin in the renal than in the coronary vasculature [172].
In conscious dogs, renal vasoconstriction persists up to 40
minutes after cessation of the infusion of endothelin, demon-
strating the prolonged action of the peptide [1731.
Demonstration of endothelin messenger RNA expression in
the vasa recta and medulla supports the concept of a local
production and action of the peptide within the kidney [179].
Indeed, in the rat, the renal medulla contains the highest
concentrations of endothelin in the body [180]. Endothelin not
only is produced by endothelial cells of the renal microvascu-
lature [179] and the glomeruli [181], but also by renal tubular
cells in culture [182, 1831. Most likely, the isoform of the
peptide produced by these cells is endothelin-3 [Yanagisawa H,
personal communication].
Binding sites for endothelin-l occur with high density in the
vasa recta and papilla of rat, pig and human kidneys [184-186].
In the renal cortex binding sites for the peptide occur with a
lesser density and local endothelin production is less pro-
nounced [180, 184—187]. Rat mesangial cells possess specific
receptors for endothelin [187]. Endothelin contracts mesangial
cells of the rat (associated with activation of phospholipase C
and increases in intracellular calcium [175, 1881 and reduces
glomerular filtration rate by increasing afferent and efferent
resistance and decreasing the ultrafiltration coefficient [74, 174,
176]. In addition, endothelin is a potent mesangial mitogen [74,
188]. Mitogenesis induced by the peptide is associated with
activation of phospholipase C, increases in intracellular cal-
cium, cytosolic alkalinization (via activation of Na/H ex-
change) and enhanced transcription of the c-fos protooncogenes
[1881. Rat mesangial cells contain a low and high affinity
receptor for the peptide with the former mediating these re-
sponses [1871. Bovine glomerular endothelial cells do indeed
express endothelin messenger RNA in response to bradykinin,
ADP, thrombin and platelet activating factor, suggesting that
the peptide may act as a local regulatory system of glomerular
function [181]. While binding of endothelin occurs in rat gb-
meruli, it remains controversial whether binding sites exist
within human glomeruli [184—1861. Thus, although in rats en-
dothelin- 1 provokes dramatic decreases in the glomerular ul-
trafiltration coefficient [175], it remains uncertain whether sim-
ilar effects occur in humans.
The renin secretion of cortical slices of canine kidney is
markedly reduced, if they are superfused with bradykinin or
acetylcholine passing through either a column of endothelial
cells in culture or an arterial segment with endothelium [38, 39].
This suggests that EDRF released from endothelial cells inhibits
renal renin production. Since endothelial cells respond to shear
forces exerted by the circulating blood, this response may
mediate the renal renin-baroreceptor mechanism. Endothelin
also reduces renin production by juxtaglomerular cells in vitro
[189]. In vivo, however, the profound vasoconstrictor effects of
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the peptide predominate and increase renin secretion [75]. In
addition, endothelin stimulates the production of atrial natri-
uretic peptide in the heart [92, 1901, the release of aldosterone
from adrenocortical glomerulosa cells and inhibits the antidi-
uretic effects of vasopressin in vivo (probably through an
inhibition of adenylate cyclase activation) [172, 1911. Stimula-
tion of the secretion of atrial natriuretic peptide appears to
mediate endothelin-induced natriuresis in the rat [1901. Al-
though all these effects of the peptide ultimately affect renal
function, their individual importance remains to be defined.
Thus, endothelium-derived nitric oxide and endothelin can
profoundly affect mesangial cells, juxtaglomerular cells, gb-
merular function and renal hemodynamics (Table 1) and may
act as a local regulatory system of kidney function under
physiological conditions.
Endothelium and kidney disease
Because of its strategical anatomical position between the
circulating blood and vascular smooth muscle, juxtaglomerular
and mesangial cells, the endothelium may play a prominent role
as a target of renal injuries such as ischemia, hypertension,
renal transplant rejection, toxic agents and drugs. In fact, the
changes induced by these stimuli may mediate or promote
alterations in renal hemodynamics and function characteristic
of certain kidney diseases.
Acute renal failure
Acute renal failure is a syndrome that arises in response to a
wide variety of insults to the kidneys [192]. Alterations in renal
hemodynamics develop in all forms of acute renal failure. The
hallmark of the ischemic form of acute renal failure is a
profound diminution in glomerular filtration rate that is dispro-
portionate to the observed decrease in renal blood flow as well
as an abnormal renovascular reactivity [192]. In ischemic acute
renal failure of the rat, the renal vasodilator response to
acetylcholine and bradykinin is lost, renal blood flow decreases
in an exaggerated fashion to renal nerve stimulation, and
reductions of renal perfusion pressure within the normal auto-
regulatory range provoke a paradoxical vasoconstriction which
further decreases renal blood flow [193, 194]. Similar functional
abnormalities occur in isolated perfused kidneys after pro-
longed ischemia [195]. This suggests that, as in the coronary
circulation [196, 197], ischemia reduces the production of
EDRF (and possibly that of prostacyclin) from injured endothe-
hal cells; this could, at least in part, explain the increased
sensitivity of vascular smooth muscle to constricting sub-
stances (released from adrenergic nerves or circulating in the
blood) and the increase in basal tone of the postischemic renal
microvasculature. Hemoglobin and myogbobin, both potent
inhibitors of EDRF [198, 199], exert similar hemodynamic
effects in the renal circulation and these mechanisms may
importantly contribute to renal failure in patients with hemoly-
sis and crush syndrome.
In addition, the injured endothelium can serve as the source
of increased production of vasoconstrictor substances such as
free radicals [99], endothelin [66, 68], thromboxane A2 [2] or
angiotensin II (Fig. 2) [591. In patients with acute renal failure,
plasma endothelin levels are elevated and they decline during
recovery from the disease [200]. Although a decreased clear-
ance of the peptide could contribute, ischemia may stimulate
endothelin production [661. In line with that interpretation,
increased levels of the peptide have been noted in acute
myocardial infarction [201]. In ischemic acute renal failure of
the rat, infusion of antiendothelin antibody into one of the
branches of the main renal artery ameliorates the vasoconstric-
tion characteristic of postischemic nephrons [174]. Direct mi-
cropuncture measurements of glomeruli exposed to the endo-
thelin antibody demonstrate a marked increase in single
nephron glomerular filtration rate and renal plasma flow, and
concomitant decrease in afferent and efferent arteriolar resis-
tance following infusion of the antibody [174]. Thus, locally
produced endothelin may be an important factor in the patho-
genesis of ischemic acute renal failure.
Platelet activating factor has been implicated in the patho-
genesis of endotoxemic acute renal failure of the rat [203].
Although the substance is released by endothelial cells [53, 541,
the specific contribution of endothelium-derived platelet acti-
vating factor remains to be demonstrated as it can also be
produced and released by numerous other cells (for example,
platelets, smooth muscle and mesangial cells).
Chronic renal failure
Proliferation of mesangial, endothelial and gbomerular epithe-
hal cells is a prominent feature of many forms of gbomerubone-
phritis. Endothelial cells are a source of growth promoters (that
is, platelet-derived growth factors) and inhibitors (heparin sul-
fates) [204]. In addition, endothelium-derived vasoactive sub-
stances also can affect growth of vascular smooth muscle and
mesangial cells [80, 2051. Activation of cGMP in vascular
smooth muscle cells (by substances releasing nitric oxide), is
associated with a decreased thymidine incorporation and pro-
liferation of vascular smooth muscle cells in culture [205].
Endothelin, on the other hand, is a potent mesangial mitogen
[80]. Thus, a reduced release of EDRF and/or an increased
production of endothelin, particularly if occurring in glomerular
endothehial cells, could contribute to the pathogenesis of certain
proliferative forms of glomerubonephritis. Indeed, the endothe-
hum is a target organ of various mediators of inflammation.
Some of them such as interleukin- 1 stimulate endothelin pro-
duction [206], while others such as tumor necrosis factor reduce
the release of EDRF [207]. If persistent, these changes in
endothelium function may contribute to the non-immunological
progression of kidney disease where gbomerular hypertrophy
appears an important pathogenetic mechanism [208]. Lipids,
which also alter endothelium function, may further facilitate
these changes [2081. Thus, alterations in the production of
endothelial growth inhibitors (nitric oxide, heparins and hepar-
insulfates) and growth promoters (endothehin, platelet-derived
growth factor) may contribute to this process.
Although not much is known about endothehial function in
chronic renal failure, marked alterations of endothelium func-
tion are likely to occur under these conditions. Hypertension,
hyperlipidemia and diabetes [2] which are frequently associated
with end stage kidney disease may importantly contribute to
such changes and in particular to the increased cardiovascular
morbidity and mortality of these patients. In patients receiving
hemodiahysis for chronic renal failure, circulating endothehin
levels are elevated, a phenomenon which may be related to
renal failure or to the dialysis treatment [209, 210]. Whether the
increased endothelin levels are due to a reduced clearance
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and/or to an increased production of the peptide remains to be
determined.
Cyclosporine
Cyclosporin A is a potent immunosuppressive fungal peptide
which is effective in the prevention of acute organ allograft
rejection [211—2141. Its use is complicated by side effects, the
most prominent ones are nephrotoxicity and hypertension [211,
215—219]. Cyclosporine nephrotoxicity is characterized by early
reversible decreases in glomerular filtration rate and renal blood
flow [218, 219]. In addition, hypertension is a common compli-
cation of long-term therapy with the immunosuppressive agent
[2111. Cyclosporine-induced endothelial cell vacuolization and
necrosis and thrombosis has been noted in renal arterioles and
glomeruli suggesting that the cells are an important target of the
drug [219—221]. An imbalance between endothelium-derived
relaxing and contracting factors induced by cyclosporin A could
contribute to changes of the renal circulation and of renal
function as well as to hypertension occurring during chronic
administration of the drug.
Indeed, recent experimental studies demonstrate functional
alterations of endothelial cells induced by cyclosporin A. In
endothelial or mesangial cells in culture, cyclosporin A in-
creases the production of thromboxane A2 and decreases that of
prostacyclin [219—2211. In perfused kidneys of rats treated
chronically with cyclosporin A, the vasodilator response to
acetylcholine is reduced [222]. Similarly, endothelium-depen-
dent relaxations are impaired in isolated renal arteries and in
aortic rings of rats treated chronically with cyclosporin A [223,
224]. As only low [2221, but not high daily doses of the drug
[223] are associated with an elevated blood pressure and an
endothelial dysfunction has been noted under both conditions,
cyclosporin A must directly interfere with endothelium func-
tion. In line with that interpretation, acute incubation of iso-
lated human subcutaneous resistance arteries with cyclosporin
A reduces endothelium-dependent relaxations to acetyicholine
[2251.
The impaired endothelium-dependent relaxations induced by
cyclosporin A are related to stimulation of the release of
contracting factors from the endothelium, a decreased release
of EDRF(s) and particularly with prolonged therapy a reduced
responsiveness of vascular smooth muscle to EDRF [223—226].
In the rat renal artery [223] inhibition of cyclooxygenase with
indomethacin enhances the impaired endothelium-dependent
relaxations to acetylcholine to cyclosporin A treated animals,
indicating that the drug facilitates the production of a cycloox-
ygenase-dependent endothelium-derived contracting factor
(EDCF2) (Fig. 2) [2]. Although cyclosporin A nephrotoxicity is
associated with an increased urinary excretion of thromboxane
B2, and 2,3-dinor thromboxane B2 [227, 2281, another vasocon-
strictor prostanoid must be involved under these conditions as
thromboxane synthetase inhibitors do not normalize the relax-
ations.
In addition, high dosages of cyclosporin A increase endothe-
lin-1 binding sites in cardiac cell membranes [229]. In human
venous, but not glomerular endothelial cells in culture, the drug
also stimulates the production of endothelin [230]. In rats and
possibly also in patients cyclosporin A also stimulates the
formation of the peptide in vivo [231]. Both events would lead
to an imbalance of endothelium-derived contracting and relax-
ing factors and favor vasoconstriction which may contribute to
the changes in renal hemodynamics and systemic blood pres-
sure occurring during chronic therapy with the drug. Indeed, in
isolated perfused kidneys of the rat, antibodies against endo-
thelin-l largely prevent the acute hemodynamic effects of
cyclosporine [231—233].
Cyclosporin A also enhances platelet aggregation induced by
ADP, adrenalin and collagen and increases thromboxane A2
release from platelets [2341. Particularly, in the context of a
reduced vascular formation of EDRF (and that of prostacyclin),
this would be associated with an increased platelet-vessel wall
interaction (Fig. 4) which may favor vasoconstriction and
intravascular thrombosis in the renal circulation. Indeed, gb-
merular thrombosis and hemolytic-uremic syndrome are recog-
nized potential complications of cyclosporine therapy [235—
2371.
Conclusion
The endothelium produces and releases substances which
can profoundly affect the function of vascular smooth muscle,
juxtaglomerular, mesangial and possibly also tubular cells [2,
238]. Hence, alterations of the release of endothelium-derived
relaxing and contracting factors under physiological conditions
and in renal disease cause marked changes in renal hemody-
namics and function. Under physiological conditions, the re-
lease of EDRF contributes to normal renal function as its
inhibition leads to a marked decrease of renal blood flow.
Ischemic renal failure, hypertension, diabetes, hyperlipidemia,
atherosclerosis and cyclosporin A toxicity are associated with a
decreased formation of EDRF and (at least under certain
experimental conditions) an increased formation of contracting
factors such as endothelin and EDCF2 [2, 2381. Thus, the
endothelium may act as a target and mediator of injurious
stimuli to the kidney. Further research is needed, however, to
substantiate this new and promising perspective in nephrology.
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